Amgenvs.United Therapeutics
AMGN vs UTHR · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Amgen is about 10× larger than United Therapeutics by market cap; United Therapeutics trades at the lower P/E (17.0 vs 25.8); year to date, Amgen leads (+35.6% vs +5.3%).
Side by side
| AMGN | UTHR | |
|---|---|---|
| Market cap | $226B | $22.3B |
| Price | $442.24 | $518.53 |
| Today | −0.4% | +1.1% |
| Return YTD | +35.6% | +5.3% |
| Return 1Y | +51.1% | +64.3% |
| P/E | 25.8 | 17.0 |
| P/S | 5.9 | 7.1 |
| P/B | 19.3 | 3.5 |
Data as of 2026-08-26 · updates daily after U.S. close
The two companies
AmgenAMGN
Long-established in biotech, with oncology and haematology at the centre of the portfolio, immunology beside it and a line in bone disease. MariTide is the obesity candidate in the pipeline.
Full AMGN profile →United TherapeuticsUTHR
Pulmonary hypertension accounts for the marketed drugs, Tyvaso, Remodulin and Orenitram among them. A separate programme works on organs for transplant, including xenotransplantation.
Full UTHR profile →More AMGN & UTHR comparisons
Other head-to-heads in the Biotech & innovation segment.